Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KHK | P50053 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094778 | 0.87 | TSHR (0.39) | TSHRSIGMAR1POLBUSP2 | |
| SCHEMBL19226645 | 0.83 | TSHR (0.43) | TSHRSIGMAR1POLBUSP2 | |
| SCHEMBL14044233 | 0.81 | TSHR (0.35) | TSHRSIGMAR1POLB | |
| SCHEMBL3993856 | 0.81 | SIGMAR1 (0.37) | TSHRSIGMAR1KHKL3MBTL3L3MBTL1 | |
| SCHEMBL21038319 | 0.80 | HTR6 (0.46) | TSHRSIGMAR1POLBUSP2TLR9 | |
| SCHEMBL21214477 | 0.76 | L3MBTL1 (0.36) | TSHRSIGMAR1L3MBTL3L3MBTL1 | |
| SCHEMBL6627321 | 0.76 | POLB (0.32) | SIGMAR1POLBGNAO1 | |
| SCHEMBL22921130 | 0.76 | L3MBTL3 (0.38) | TSHRL3MBTL3L3MBTL1 | |
| SCHEMBL19226796 | 0.76 | SIGMAR1 (0.36) | TSHRSIGMAR1 | |
| SCHEMBL3159987 | 0.76 | HTR6 (0.41) | TSHRKHKL3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048288-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | TSHR 3168/4885SIGMAR1 3576/4885KHK 1084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.